CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need. Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts' lead drug candidate, GP1681, is positioned to become a new best practice in medicine.